TITANBIOSpecialty Chemicals
Titan Bio Tech Ltd — Profit & Loss Statement
₹457.70
+4.87%
Titan Bio Tech Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -74906.78 | -5029.31 | — |
| Tax Rate For Calcs | 0.25 | 0.25 | 0.25 | 0.25 | — |
| Normalized EBITDA | 29.34 Cr | 36.03 Cr | 31.31 Cr | 32.03 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 21.53 Cr | 24.85 Cr | 24.84 Cr | 21.68 Cr | — |
| Reconciled Depreciation | 4.17 Cr | 3.33 Cr | 2.60 Cr | 2.37 Cr | — |
| Reconciled Cost Of Revenue | 72.63 Cr | 75.61 Cr | 85.64 Cr | 70.53 Cr | — |
| EBITDA | 29.34 Cr | 36.03 Cr | 31.28 Cr | 32.03 Cr | — |
| EBIT | 25.17 Cr | 32.70 Cr | 28.68 Cr | 29.66 Cr | — |
| Net Interest Income | -0.80 Cr | -1.17 Cr | -0.70 Cr | -0.76 Cr | — |
| Interest Expense | 0.80 Cr | 1.17 Cr | 0.56 Cr | 0.69 Cr | — |
| Normalized Income | 21.53 Cr | 24.85 Cr | 24.87 Cr | 21.69 Cr | — |
| Net Income From Continuing And Discontinued Operation | 21.53 Cr | 24.85 Cr | 24.84 Cr | 21.68 Cr | — |
| Total Expenses | 135.19 Cr | 133.12 Cr | 117.00 Cr | 94.65 Cr | — |
| Diluted NI Availto Com Stockholders | 21.53 Cr | 24.85 Cr | 24.84 Cr | 21.68 Cr | — |
| Net Income Common Stockholders | 21.53 Cr | 24.85 Cr | 24.84 Cr | 21.68 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 21.53 Cr | 24.85 Cr | 24.84 Cr | 21.68 Cr | — |
| Net Income Including Noncontrolling Interests | 21.53 Cr | 24.85 Cr | 24.84 Cr | 21.68 Cr | — |
| Net Income Continuous Operations | 21.53 Cr | 24.85 Cr | 24.84 Cr | 21.68 Cr | — |
| Tax Provision | 6.10 Cr | 7.87 Cr | 7.09 Cr | 7.28 Cr | — |
| Pretax Income | 24.37 Cr | 31.53 Cr | 28.12 Cr | 28.97 Cr | — |
| Other Non Operating Income Expenses | 3.91 Cr | 1.75 Cr | 1.85 Cr | 0.83 Cr | — |
| Net Non Operating Interest Income Expense | -0.80 Cr | -1.17 Cr | -0.70 Cr | -0.76 Cr | — |
| Interest Expense Non Operating | 0.80 Cr | 1.17 Cr | 0.56 Cr | 0.69 Cr | — |
| Operating Income | 21.26 Cr | 30.95 Cr | 27.00 Cr | 28.90 Cr | — |
| Operating Expense | 62.57 Cr | 57.52 Cr | 31.36 Cr | 24.12 Cr | — |
| Other Operating Expenses | 32.02 Cr | 30.47 Cr | 0.91 Cr | 0.94 Cr | — |
| Depreciation And Amortization In Income Statement | 4.17 Cr | 3.33 Cr | 2.60 Cr | 2.37 Cr | — |
| Depreciation Income Statement | 4.17 Cr | 3.33 Cr | 2.57 Cr | 2.35 Cr | — |
| Gross Profit | 83.82 Cr | 88.47 Cr | 58.36 Cr | 53.02 Cr | — |
| Cost Of Revenue | 72.63 Cr | 75.61 Cr | 85.64 Cr | 70.53 Cr | — |
| Total Revenue | 156.45 Cr | 164.07 Cr | 144.00 Cr | 123.55 Cr | — |
| Operating Revenue | 156.45 Cr | 164.07 Cr | 144.00 Cr | 123.55 Cr | — |
| Total Unusual Items | — | 0.00 | -0.03 Cr | -20000.00 | -0.73 Cr |
| Total Unusual Items Excluding Goodwill | — | 0.00 | -0.03 Cr | -20000.00 | -0.73 Cr |
| Interest Income | — | 0.09 Cr | 0.04 Cr | 0.11 Cr | 0.06 Cr |
| Rent Expense Supplemental | — | 0.33 Cr | 38000.00 | 0.00 | 0.14 Cr |
| Diluted Average Shares | — | 0.83 Cr | 0.83 Cr | 0.83 Cr | 0.83 Cr |
| Basic Average Shares | — | 0.83 Cr | 0.83 Cr | 0.83 Cr | 0.83 Cr |
| Diluted EPS | — | 30.07 | 30.06 | 26.24 | 36.71 |
| Basic EPS | — | 30.07 | 30.06 | 26.24 | 36.71 |
| Special Income Charges | — | 0.00 | -0.08 Cr | -20000.00 | -0.73 Cr |
| Write Off | — | 0.00 | 0.08 Cr | 0.00 | 0.21 Cr |
| Total Other Finance Cost | — | 0.23 Cr | 0.18 Cr | 0.18 Cr | 0.25 Cr |
| Interest Income Non Operating | — | 0.09 Cr | 0.04 Cr | 0.11 Cr | 0.06 Cr |
| Amortization | — | 0.03 Cr | 0.03 Cr | 0.02 Cr | 92085.50 |
| Selling General And Administration | — | 11.16 Cr | 9.64 Cr | 6.57 Cr | 5.58 Cr |
| Selling And Marketing Expense | — | 8.76 Cr | 7.80 Cr | 5.17 Cr | 4.28 Cr |
| General And Administrative Expense | — | 2.39 Cr | 1.84 Cr | 1.40 Cr | 1.30 Cr |
| Rent And Landing Fees | — | 0.33 Cr | 38000.00 | 0.00 | 0.14 Cr |
| Minority Interests | — | — | — | -3.22 Cr | -1.37 Cr |
| Other Special Charges | — | — | — | 20000.00 | 0.33 Cr |
| Impairment Of Capital Assets | — | — | — | 0.00 | 0.19 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Titan Bio Tech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.